About Us

Veloxis is a specialty pharmaceutical company focused on the development of pharmaceutical products in the field of immunosuppression as well as in other specialty therapeutic areas. Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in New Jersey, US. Veloxis (formerly LCP) was founded in June 2002 as a spin-off from H. Lundbeck A/S and is listed on NASDAQ OMX Copenhagen A/S (OMX: VELO).

Veloxis uses its proprietary MeltDose® technology, which has been validated in clinical studies and through FDA approval of Fenoglide®, to enhance the bioavailability of existing marketed drugs, which could lead to lower dose, less frequent dosing and/or fewer side effects for compounds with low water solubility. Additionally compounds can be formulated to allow for a controlled- or modified-release plasma profile.

Veloxis has a pipeline with 1 phase 3 program (LCP-Tacro™ for stable and de novo kidney transplant patients), 1 phase 2 program (LCP-Tacro™ for liver transplant patients), 1 completed phase 2 program (AtorFen™ for dyslipidemia), 1 completed phase 1 program (LCP-Feno™ for dyslipidemia), and several compounds in early stage preclinical development. Following encouraging results from LCP-Tacro™ phase 2 clinical studies, Veloxis has decided to focus its development efforts on LCP-Tacro™ for the treatment of kidney transplant patients.

LCP-Tacro™ is the leading Veloxis transplant immunosuppression product candidate. Top-line results from a clinical phase 3 study in stable kidney transplant patients were announced in June 2011. In this non-inferiority study, LCP-Tacro™ dosed once a day successfully met all primary efficacy and safety end points when compared with the current leading transplant drug, Prograf®, dosed twice a day. The results were achieved with significantly lower doses of LCP-Tacro™ compared with Prograf®. Top-line results from a clinical phase 3 study in patients who just received a kidney transplant (de novo) are expected by early 2013, after which Veloxis expects to submit applications for registration in the EU and US, respectively, in the first half of 2013.

Veloxis has internationally experienced management and key employees consisting of biopharmaceutical executives and recognized experts who offer diverse backgrounds and complementary skill sets in research, development, drug approval, commercialization, and finance. Veloxis management and key employees draw from experience gained at leading pharmaceutical and biotechnology companies such as Novartis Pharmaceuticals Corporation, Novo Nordisk, and Wyeth Pharmaceuticals (acquired by Pfizer Inc).